Research Analysts Offer Predictions for ZVRA Q2 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – HC Wainwright increased their Q2 2026 earnings per share estimates for Zevra Therapeutics in a report released on Thursday, May 7th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings per share of $0.06 for the quarter, up from their prior estimate of $0.03. The consensus estimate for Zevra Therapeutics’ current full-year earnings is $0.44 per share. HC Wainwright also issued estimates for Zevra Therapeutics’ Q3 2026 earnings at $0.11 EPS, Q4 2026 earnings at $0.17 EPS, FY2027 earnings at $1.06 EPS, FY2028 earnings at $1.49 EPS, FY2029 earnings at $2.45 EPS and FY2030 earnings at $3.18 EPS.

A number of other research analysts also recently commented on the company. BTIG Research initiated coverage on Zevra Therapeutics in a report on Monday, March 16th. They set a “buy” rating and a $23.00 target price on the stock. Weiss Ratings raised Zevra Therapeutics from a “sell (d+)” rating to a “hold (c+)” rating in a report on Tuesday, March 10th. Guggenheim set a $23.00 target price on Zevra Therapeutics and gave the stock a “buy” rating in a report on Tuesday, March 10th. Finally, Wall Street Zen raised Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, April 11th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $23.00.

Zevra Therapeutics Price Performance

Shares of NASDAQ ZVRA opened at $11.00 on Friday. Zevra Therapeutics has a fifty-two week low of $7.16 and a fifty-two week high of $13.16. The business has a 50 day moving average price of $9.73 and a two-hundred day moving average price of $9.25. The company has a quick ratio of 5.63, a current ratio of 5.68 and a debt-to-equity ratio of 0.40. The firm has a market cap of $650.32 million, a PE ratio of 5.53 and a beta of 0.88.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.18 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.12. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 58.24%. The firm had revenue of $36.22 million for the quarter, compared to analyst estimates of $31.96 million.

Institutional Trading of Zevra Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. CWM LLC increased its position in shares of Zevra Therapeutics by 399.5% during the 3rd quarter. CWM LLC now owns 2,872 shares of the company’s stock valued at $27,000 after purchasing an additional 2,297 shares during the period. Gunpowder Capital Management LLC dba Oliver Wealth Management acquired a new position in shares of Zevra Therapeutics during the 4th quarter valued at $53,000. Russell Investments Group Ltd. increased its position in shares of Zevra Therapeutics by 235.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after purchasing an additional 4,475 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Zevra Therapeutics by 617.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after purchasing an additional 8,552 shares during the period. Finally, Creative Planning acquired a new position in shares of Zevra Therapeutics during the 2nd quarter valued at $92,000. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics News Roundup

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: Q1 results beat Street estimates — Zevra reported GAAP EPS of $0.18 versus the consensus $0.06 and revenue of $36.2M vs. ~$32M expected; management highlighted strong margins and profitability. This is the primary positive driver behind recent buying interest. Zevra Reports First Quarter 2026 Financial Results and Corporate Update
• Positive Sentiment: Strong profitability metrics — the company reported a very high net margin (~78%) and return on equity (~57%), and Zacks/MarketBeat coverage also flagged the beat. Those metrics support a re‑rating from investors focused on near‑term earnings. Zacks: Q1 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Portfolio sale boosts liquidity — Zevra completed a $50.0M sale of its SDX portfolio to Commave Therapeutics, pushing cash to about $236.8M and improving the balance sheet to fund growth or M&A. That reduces financing risk and is a catalyst for longer‑term investors. GlobeNewswire press release
• Neutral Sentiment: Multiple transcripts and call coverage available — full earnings‑call transcripts and corporate commentary were published by Seeking Alpha, The Motley Fool, InsiderMonkey and Chron, useful for investors wanting management color on growth drivers and use of proceeds. SA transcript Fool transcript Chron snapshot
• Negative Sentiment: Short‑term profit‑taking / valuation debate — after a recent share‑price surge (and higher trading volume), some investors and outlets question whether it’s too late to buy, which can pressure the stock as traders lock in gains. That debate likely explains why shares are trading down today. Yahoo: Is It Too Late To Consider ZVRA?
• Negative Sentiment: Elevated intraday volume — volume was roughly 2.6M vs. an average ~1.04M, which can amplify moves on both buying and selling; today it accompanied selling pressure. MarketBeat summary

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.